Evidence map›Paper›PMID 29969371›Full record

ArticleCell cycle (Georgetown, Tex.)2018

Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.

Bolun Wang, Hui Lyu, Shanshan Pei, Deye Song, Jiangdong Ni, Bolin Liu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Bolun Wanga Department of Orthopedics , The Second Xiangya Hospital, Central South University , Changsha , China.
Hui Lyub School of Medicine , University of Colorado Anschutz Medical Campus , Aurora , CO , USA.
Shanshan Peic Department of Hematology , School of Medicine, University of Colorado Anschutz Medical Campus , Aurora , CO , USA.
Deye Songa Department of Orthopedics , The Second Xiangya Hospital, Central South University , Changsha , China.
Jiangdong Nia Department of Orthopedics , The Second Xiangya Hospital, Central South University , Changsha , China.
Bolin Liub School of Medicine , University of Colorado Anschutz Medical Campus , Aurora , CO , USA.
Second Xiangya Hospital of Central South University · CNUniversity of Colorado Anschutz Medical Campus · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
ErbB3-miRNA axis in tumor metastasis of erbB2-positive breast cancerR01CA201011 · NCI · UNIVERSITY OF COLORADO DENVER · PI LIU, BOLIN · 2016 to 2020
$1.7M
NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA201011
6 · The paper itself

Abstract

Cladribine (2CdA), a synthetic purine analog interfering with DNA synthesis, is a medication used to treat hairy cell leukemia (HCL) and B-cell chronic lymphocytic leukemia. Entinostat, a selective class I histone deacetylase (HDAC) inhibitor, shows antitumor activity in various human cancers, including hematological malignancies. The therapeutic potential of cladribine and entinostat against multiple myeloma (MM) remains unclear. Here we investigate the combinatorial effects of cladribine and entinostat within the range of their clinical achievable concentrations on MM cells. While either agent alone inhibited MM cell proliferation in a dose-dependent manner, their combinations synergistically induced anti-proliferative/anti-survival effects on all MM cell lines (RPMI8226, U266, and MM1.R) tested. Further studies showed that the combinations of cladribine and entinostat as compared to either agent alone more potently induced mitotic catastrophe in the MM cells, and resulted in a marked increase of the cells at G1 phase associated with decrease of Cyclin D1 and E2F-1 expression and upregulation of p21 ABBREVIATIONS: MM, multiple myeloma; HCL, hairy cell leukemia; HDAC, histone deacetylase; Ab, antibody; mAb, monoclonal Ab; FBS, fetal bovine serum; CI, combination index; PAGE, polyacrylamide gel electrophoresis; ELISA, enzyme-linked immunosorbent assay; PARP, poly(ADP-ribose) polymerase; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,inner salt.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsApoptosisBenzamidesCell Line, TumorCell ProliferationCell SurvivalCladribineDNA DamageDrug SynergismG1 Phase Cell Cycle CheckpointsGene Expression Regulation, NeoplasticHumansMitosisMultiple MyelomaPyridinesBenzamidesCladribineentinostatPyridinesCladribineentinostatmultiple myeloma

Identifiers

PMID29969371
PMCPMC6197031
OpenAlexW2811499234

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.